Presence and role of Simian Virus 40 (SV40) in malignant pleural mesothelioma

Hmeljak, Julija; Cör, Andrej

doi:10.2478/v10019-009-0009-9

Cited by 26 publications

(72 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cases of mesothelioma without prior exposure to asbestos are rare and usually occur as a consequence of repeated mesothelial scarring or irradiation (Churg et al 2004). A role of Simian virus 40 in MPM pathogenesis has been speculated in the past, but consensus has not been achieved (Hmeljak and Cor 2009). Twenty-nine new MPM cases were diagnosed in Slovenia in 2007, accounting for an approximate incidence of 1.5 per 100,000.…”

Section: Introductionmentioning

confidence: 98%

BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients

Hmeljak

Erčulj

Dolžan

et al. 2011

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 98%

BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients

Hmeljak

Erčulj

Dolžan

et al. 2011

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The genome of SV40 is a single, circular, doublestranded DNA molecule functionally divided into three distinct regions: early, late and regulatory. The early region is expressed soon after entry into the cell, whereas the late region, encoding for capsid proteins, is expressed only after successful viral DNA replication within the permissive host cell 10 . Viral oncogenicity is mediated by the products of two genes encoded on the early region, large T (Tag) and small t (tag) antigen.…”

Section: Introductionmentioning

confidence: 99%

No Implication of Simian virus 40 in pathogenesis of Malignant Pleural Mesothelioma in Slovenia

Hmeljak

Kern

Cör

2010

Tumori

Self Cite

View full text Add to dashboard Cite

show abstract

“…The other putative aetiological factor, Semian virus 40, was not implicated in pathogenesis of malignant pleural mesothelioma in Slovenia. 23 , 24 …”

Section: Discussionmentioning

confidence: 99%

Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients

Kovač¹,

Zwitter²,

Žagar³

2012

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundMalignant pleural mesothelioma is a rare tumour with increasing frequency throughout the world. Due to long latency after exposure to asbestos, restrictions in the production and use of asbestos have not yet alleviated the burden of mesothelioma. During the last decade, several trials confirmed the benefit of systemic treatment with drugs such as doublets with cisplatina and gemcitabine or pemetrexed for carefully selected patients in good performance status. The purpose of this survey was to assess the impact of systemic treatment for the whole national population of patients with mesothelioma.Patients and methods.A retrospective study included all patients in Slovenia with histologically confirmed diagnosis of malignant pleural mesothelioma in the period from 1974 till 2008. Data from the Cancer Registry of Slovenia were supplemented by review of clinical records of the Institute of Oncology in Ljubljana where virtually all non-surgical treatment for mesothelioma was performed. We analysed the incidence, treatment, and survival of patients treated in the era of infrequent chemotherapy (1974–2003, the first period) and after it (2004–2008, the second period).ResultsThe survey included 444 patients, of whom 325 and 119 were diagnosed in the first and second period, respectively. Joinpoint regression analysis showed that after 1995 the trend in crude incidence rates increased more rapidly; the annual change was 0.03 per 100,000 per year before 1995 and 0.06 per 100,000 per year after. There was clear male predominance (70%) throughout the period covered by the survey. The proportion of patients above 65 years of age increased from 41.8% to 54.6% for the first and second period, respectively (p = 0.02). With a total of 52 (11.7%) operated patients, surgical treatment was rare and used only for selected patients with early disease and without comorbidity, leading to their relatively long median survival of 13.6 months. Chemotherapy was applied to 56 (17.2%) and to 96 (80.7%) patients during the first and second period, respectively. While a variety of older drugs were used in the first period, the most common regimen in the second period (applied to 91 patients) was doublet of low-dose gemcitabine in prolonged infusion and cisplatin. For the whole population of patients regardless the mode of treatment, median survival was 7.4 and 12.6 months (p-value = 0.037) for the first and second period, respectively.ConclusionsIncreasing incidence, male predominance and increased proportion of older patients confirm that the burden of mesothelioma persists in spite of a 15-years old ban in the production of asbestos. Modern chemotherapy, and in particular treatment with low-dose gemcitabine in prolonged infusion and cisplatin significantly prolonged median survival of patients with malignant pleural mesothelioma in Slovenia.

show abstract

Presence and role of Simian Virus 40 (SV40) in malignant pleural mesothelioma

Cited by 26 publications

References 16 publications

BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients

BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients

No Implication of Simian virus 40 in pathogenesis of Malignant Pleural Mesothelioma in Slovenia

Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients

Contact Info

Product

Resources

About